logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

ESMO 2019 — Nivolumab beats sorafenib on tolerability in advanced hepatocellular carcinoma

But overall CheckMate-459 results were disappointing and didn’t reach the primary endpoint.